Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer

Mori, Giorgia; Pasca, Maria Rosalia

doi:10.3390/ijms22031312

Cited by 17 publications

(11 citation statements)

References 174 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous data support that altered microbiota communities can modulate the efficacy of anticancer drugs via mediating or modifying the environmental factors of colon cancer ( Nakatsu et al, 2015 ; Mori and Pasca, 2021 ). The proportional imbalance between pathogenic and beneficial bacteria aggravates intestinal mucositis.…”

Section: Discussionmentioning

confidence: 99%

Standardized Astragalus Mongholicus Bunge-Curcuma Aromatica Salisb. Extract Efficiently Suppresses Colon Cancer Progression Through Gut Microbiota Modification in CT26-Bearing Mice

Sun

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Altered gut microbiota and a damaged colon mucosal barrier have been implicated in the development of colon cancer. Astragalus mongholicus Bunge-Curcuma aromatica Salisb. (ACE) is a common herbal drug pair that widely used clinically to treat cancer. However, whether the anti-cancer effect of ACE is related to gut microbiota remains unclear yet. We standardized ACE and investigated the effects of ACE on tumour suppression and analyze the related mechanisms on gut microbiota in CT26 colon cancer-bearing mice in the present study. Firstly, four flavonoids (calycosin-7-glucoside, ononin, calycosin, formononetin) and three astragalosides (astragaloside A, astragaloside II, astragaloside I) riched in Astragalus mongholicus Bunge, three curcumins (bisdemethoxycurcumin, demethoxycurcumin, curcumin) and four essential oils (curdione, curzerene, germacrone and β-elemene) from Curcuma aromatica Salisb., in concentrations from 0.08 to 2.07 mg/g, were examined in ACE. Then the results in vivo studies indicated that ACE inhibited solid tumours, liver and spleen metastases of colon cancer while simultaneously reducing pathological tissue damage. Additionally, ACE regulated gut microbiota dysbiosis and the short chain fatty acid content in the gut, repaired intestinal barrier damage. ACE treatment suppressed the overgrowth of conditional pathogenic gut bacteria, including Escherichia-Shigella, Streptococcus and Enterococcus, while the probiotic gut microbiota like Lactobacillus, Roseburia, Prevotellaceae_UCG-001 and Mucispirillum were increased. More interestingly, the content level of SCFAs such as propionic acid and butyric acid was increased after ACE administration, which further mediates intestinal SDF-1/CXCR4 signalling pathway to repair the integrity of the intestinal barrier, decrease Cyclin D1 and C-myc expressions, eventually suppress the tumor the growth and metastasis of colon cancer. To sum up, the present study demonstrated that ACE could efficiently suppress colon cancer progression through gut microbiota modification, which may provide a new explanation of the mechanism of ACE against colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Standardized Astragalus Mongholicus Bunge-Curcuma Aromatica Salisb. Extract Efficiently Suppresses Colon Cancer Progression Through Gut Microbiota Modification in CT26-Bearing Mice

Sun

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In FAP, there are associations with Bacteroides fragilis and Escherichia coli [ 46 ]. The role these microbes play in hereditary syndromes is unclear, and the lack of studies looking to understand this represents a massive gap in research and an opportunity to improve screening and prevention in these high-risk patients [ 106 ].…”

Section: Diagnosis and Treatment Implicationsmentioning

confidence: 99%

The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer

Tokumaru

et al. 2022

Cancers

View full text Add to dashboard Cite

The gut microbiome has long been known to play a role in various aspects of health modulation, including the pathogenesis of colorectal cancer (CRC). With immunotherapy recently emerging as a successful treatment in microsatellite instability high (MSI-high) CRC, and with a newly demonstrated involvement of the gut microbiome in the modulation of therapeutic responses, there has been an explosion of research into the mechanisms of microbial effects on CRC. Harnessing and reprogramming the microbiome may allow for the expansion of these successes to broader categories of CRC, the prevention of CRC in high-risk patients, and the enhancement of standard treatments. In this review, we pull together both well-documented phenomena and recent discoveries that pertain to the microbiome and CRC. We explore the microbial mechanisms associated with CRC pathogenesis and progression, recent advancements in CRC systemic therapy, potential options for diagnosis and prevention, as well as directions for future research.

show abstract

“…Colorectal cancer (CRC) is third in terms of incidence and second in terms of mortality worldwide. It is the most common type of cancer in men, after lung and prostate cancers, and the second most common type of cancer in women after breast cancer [139]. CRC is a disease of developed countries, because the main factors that impact tumor development are obesity, sedentary lifestyle, tobacco smoking, and the consumption of red meat and alcohol [140].…”

Section: Gastrointestinal Cancers 711 Colorectal Cancermentioning

confidence: 99%

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

Guz

Jeleniewicz

Cybulski

2022

IJMS

View full text Add to dashboard Cite

For more than two decades, the view of the roles of non-coding RNAs (ncRNAs) has been radically changing. These RNA molecules that are transcribed from our genome do not have the capacity to encode proteins, but are critical regulators of gene expression at different levels. Our knowledge is constantly enriched by new reports revealing the role of these new molecular players in the development of many pathological conditions, including cancer. One of the ncRNA classes includes short RNA molecules called microRNAs (miRNAs), which are involved in the post-transcriptional control of gene expression affecting various cellular processes. The aberrant expression of miRNAs with oncogenic and tumor-suppressive function is associated with cancer initiation, promotion, malignant transformation, progression and metastasis. Oncogenic miRNAs, also known as oncomirs, mediate the downregulation of tumor-suppressor genes and their expression is upregulated in cancer. Nowadays, miRNAs show promising application in diagnosis, prediction, disease monitoring and therapy response. Our review presents a current view of the oncogenic role of miR-1290 with emphasis on its properties as a cancer biomarker in clinical medicine.

show abstract

Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer

Cited by 17 publications

References 174 publications

Standardized Astragalus Mongholicus Bunge-Curcuma Aromatica Salisb. Extract Efficiently Suppresses Colon Cancer Progression Through Gut Microbiota Modification in CT26-Bearing Mice

Standardized Astragalus Mongholicus Bunge-Curcuma Aromatica Salisb. Extract Efficiently Suppresses Colon Cancer Progression Through Gut Microbiota Modification in CT26-Bearing Mice

The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential

Contact Info

Product

Resources

About